Squarepoint’s Stemline Therapeutics, Inc. STML Stock Holding History

Squarepoint’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-45,981	Closed	-$479K	–	2956
2019 Q3	$479K	Buy	+45,981	New	+$602K	﹤0.01%	1642
2019 Q2	–	Sell	-17,545	Closed	-$225K	–	2796
2019 Q1	$225K	Sell	17,545 -9,075	-34%	-$103K	﹤0.01%	1900
2018 Q4	$253K	Buy	26,620 +14,182	+114%	+$184K	﹤0.01%	1578
2018 Q3	$206K	Sell	12,438 -44	-0.4%	-$705	﹤0.01%	1761
2018 Q2	$200K	Buy	+12,482	New	+$223K	﹤0.01%	1543

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Squarepoint's STML Position: Q4 2019 in Review

Squarepoint sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 45,981 shares — an estimated $479K sold.

Squarepoint first reported a position in STML in Q2 2018 and held it in 5 quarters. The position peaked at $479K in Q3 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

Squarepoint reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Squarepoint sold 45,981 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $479K.
Squarepoint first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 5 quarters.
Squarepoint's Stemline Therapeutics, Inc. position peaked at $479K in Q3 2019.
99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Squarepoint's 13F filing for Q4 2019, filed 14 Feb 2020.